[Toxic epidermal necrolysis (drug-induced Lyell's syndrome). 2. Treatment].
Konstantinow
A
A
Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein der Technischen Universität München.
Mühlbauer
W
W
Balda
B R
BR
Ring
J
J
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis; D000931:Antidotes / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D003553:Cystine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D010431:Pentoxifylline / Q000627:therapeutic use; D010956:Plasmapheresis; D013262:Stevens-Johnson Syndrome / Q000188:drug therapy / Q000628:therapy*
D000305:Adrenal Cortex Hormones; D000891:Anti-Infective Agents, Local; D000931:Antidotes; D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D003553:Cystine; D016572:Cyclosporine; D003520:Cyclophosphamide; D010431:Pentoxifylline; C030905:N-monoacetylcystine